Intelligence / Healthtech / New Clinical Trials / AbbVie
Clinicaltrial registered12 Nov 2026
AbbVie
12 Nov 2026: Trial registered · A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 12 Nov 2026
- Title
- A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis
- Conditions
- Moderate to Severe Psoriasis
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07933536
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at AbbVie
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for AbbVie in our registers.
13 NovAbbVietrial registered · HealthtechClinical12 NovAbbVietrial registered · HealthtechClinical12 NovAbbVietrial registered · HealthtechClinical9 NovAbbVietrial registered · HealthtechClinical29 OctAbbVietrial registered · HealthtechClinical27 OctAbbVietrial registered · HealthtechClinical27 OctAbbVietrial registered · HealthtechClinical26 OctAbbVietrial registered · HealthtechClinical26 OctAbbVietrial registered · HealthtechClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.